Dr. Bill Williams Guest Appearance at “CEO MONEY” Radio Show
December 05 2017 - 3:41PM
BriaCell Therapeutics Corp.
("BriaCell" or the
"Company") (TSX-V:BCT) (OTCQB:BCTXF), an
immuno-oncology focused biotechnology company with a proprietary
targeted immunotherapy technology, announced today that Dr. Bill
Williams, BriaCell’s President & CEO, will appear as a guest on
the radio show "CEO MONEY."
CEO MONEY, Americas Business Show, Presented By
Michael Yorba, airs on www.1190talkradio.iheart.com at 2:00 PM
CST (3:00 PM ET, 12:00 PM PST).
To listen to the live interview of "CEO MONEY,"
please visit www.wfn1.com/listen-live.
The archive of the interview will be posted at
www.briacell.com/category/recent-events.
About WFN1
WFN1 discovers new and interesting companies and
industries with great stories that are interesting and potentially
rewarding to the investors. The interviews with business
leaders are designed to improve the public awareness of the
innovative companies and their productive ideas.
For more info. on WFN1, please visit
www.wfn1.com.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing a targeted and safe approach to
the management of cancer. BriaCell's mission is to serve late-stage
cancer patients with no available treatment options.
Immunotherapy has come to the forefront of the
fight against cancer, harnessing the body's own immune system in
recognizing and selectively destroying cancer cells while sparing
normal ones. Immunotherapy, in addition to generally being more
targeted and less toxic than commonly used types of chemotherapy,
is also thought to be a potent approach with the potential to
prevent cancer recurrence.
SV-BR-1-GM, the Company's lead product
candidate, is derived from a breast cancer cell line genetically
engineered to release granulocyte-macrophage colony-stimulating
factor (GM-CSF), a substance that activates the immune system by
allowing the body to recognize and eliminate cancerous cells by
inducing tumor-directed T cell and potentially antibody
responses.
The results of two previous Phase I clinical
trials (one with the precursor cell line not genetically engineered
to produce GM-CSF and one with SV-BR-1-GM) have been encouraging in
patients with advanced breast cancer. Most notably, one patient
with metastatic breast cancer responded to SV-BR-1-GM with
substantial reduction in tumor burden including breast, lung, soft
tissue and brain metastases. The company is currently conducting a
Phase I/IIa clinical trial for SV-BR-1-GM in patients with advanced
breast cancer. This trial is listed in ClinicalTrials.gov as
NCT03066947. The trial is being conducted along with the
co-development of BriaDx™, the Company’s companion diagnostic test.
The interim data for the first 10 patients is expected by the first
quarter of 2018. Additionally, the FDA recently approved the
roll-over combination study of SV-BR-1-GM with pembrolizumab
[Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab
[Yervoy; manufactured by Bristol-Myers Squibb Company] for patients
previously treated with SV-BR-1-GM in the Company’s ongoing Phase
I/IIa clinical trial in advanced breast cancer. The roll-over trial
is listed in ClinicalTrials.gov as NCT03328026.
BriaCell is also developing novel, selective
protein kinase C delta (PKCδ) inhibitors. PKCδ inhibitors have
shown activity in a number of pre-clinical models of RAS genes’
transformed cancers including breast, pancreatic, non-small cell
lung cancer and neuroendocrine tumors (such as carcinoid
tumors).
For additional information on BriaCell, please
visit our website: www.briacell.com
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Sep 2023 to Sep 2024